Voyager Therapeutics (VYGR) Upgraded by BidaskClub to “Buy”

Voyager Therapeutics (NASDAQ:VYGR) was upgraded by research analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Friday.

Other equities research analysts have also issued reports about the company. Cowen reissued a “buy” rating on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. Canaccord Genuity initiated coverage on Voyager Therapeutics in a research report on Friday, October 27th. They set a “buy” rating and a $35.00 price target on the stock. Stifel Nicolaus reissued a “buy” rating and set a $31.00 price target (up from $20.00) on shares of Voyager Therapeutics in a research report on Monday, October 23rd. BTIG Research initiated coverage on Voyager Therapeutics in a research report on Tuesday, December 19th. They set a “buy” rating and a $32.00 price target on the stock. Finally, Chardan Capital reissued a “hold” rating and set a $17.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have given a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $26.90.

Shares of Voyager Therapeutics (VYGR) opened at $17.86 on Friday. Voyager Therapeutics has a 52-week low of $8.10 and a 52-week high of $25.99.

In other Voyager Therapeutics news, insider Bernard Ravina sold 10,980 shares of the stock in a transaction on Tuesday, October 10th. The stock was sold at an average price of $20.33, for a total value of $223,223.40. The sale was disclosed in a document filed with the SEC, which is available through this link. Insiders sold 21,960 shares of company stock worth $370,850 over the last ninety days. 8.00% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in Voyager Therapeutics by 57.7% in the second quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock worth $106,000 after buying an additional 4,343 shares during the period. JPMorgan Chase & Co. acquired a new stake in Voyager Therapeutics in the third quarter worth $270,000. Oppenheimer & Co. Inc. acquired a new stake in Voyager Therapeutics in the second quarter worth $143,000. Rhumbline Advisers increased its position in Voyager Therapeutics by 34.7% in the second quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock worth $144,000 after buying an additional 4,144 shares during the period. Finally, Goldman Sachs Group Inc. increased its position in Voyager Therapeutics by 8.9% in the second quarter. Goldman Sachs Group Inc. now owns 17,048 shares of the company’s stock worth $153,000 after buying an additional 1,399 shares during the period. 35.97% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Voyager Therapeutics (VYGR) Upgraded by BidaskClub to “Buy”” was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://transcriptdaily.com/2018/01/07/voyager-therapeutics-vygr-upgraded-by-bidaskclub-to-buy.html.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply